DIP Episode 595 - USMLE Step 2/3 Rapid Review Series 121

Source / episode info

• Episode: 595
• Title: DIP Ep 595: USMLE Step 2/3 Rapid Review Series 121
• Published: 2025-04-23
• Source: Episode page

One-liner

This episode provides a rapid review of high-yield associations in congenital heart defects (e.g., Marfan, Down syndrome), the pathophysiology and complications of polycythemia vera (PV) and secondary polycythemia (COPD), and systemic principles like Poiseuille's Law and acquired coagulopathies.

High-yield summary

• Lithium Toxicity: Associated with Epstein's anomaly, which involves downward displacement of the tricuspid valve leaflets and often presents with associated ASD/PFO defects.
• Polycythemia Etiology: The most common cause is hypoxemia from pulmonary disease (e.g., COPD), leading to EPO release; however, malignancy (RCC, HCC) or congenital heart defects can also stimulate EPO production perinatopically.
• Polycythemia Vera (PV): This is a myeloproliferative disorder characterized by EPO-independent red blood cell proliferation (JAK2 mutation). Its complications include hyperviscosity syndrome, thrombosis, gout, and secondary hypertension.
• Vascular Principles: Increased blood viscosity increases total peripheral resistance (Poiseuille's Law), leading to increased afterload on the left ventricle, which causes concentric hypertrophy and eventually heart failure with preserved ejection fraction (H FpEF).
• PV Coagulopathy: Chronic thrombosis consumes clotting factors, resulting in an acquired deficiency of von Willebrand Factor.
• Syndromic Associations: Strong associations must be remembered: Down syndrome -> Endocardial cushion defect; Marfan Syndrome -> Mitral valve prolapse and aortic aneurysm/dissection.

Learning objectives

• Identify the specific cardiac associations for various genetic syndromes (e.g., Down syndrome, Marfan).
• Differentiate between secondary polycythemia (hypoxemic) and primary myeloproliferative disorders (PV).
• Explain the pathophysiology of hyperviscosity syndrome in Polycythemia Vera, including its impact on coagulation and circulation.
• Apply Poiseuille's Law principles to understand how increased blood viscosity affects systemic vascular resistance and cardiac workload.
• Recognize the key management steps for PV, including phlebotomy and antiplatelet therapy.

Board exam buzzwords

Rapid review table

Board-speak -> diagnosis

Differential diagnosis / distinguishing features

Congenital Cardiac Defects

Polycythemia Complications

Management pearls

• Polycythemia Vera Treatment: The cornerstone of therapy is phlebotomy (therapeutic venesection) to reduce hematocrit and decrease blood viscosity.
• Antiplatelet Therapy in PV: Aspirin is mandatory due to its irreversible inhibition of COX-1, reducing thromboxane A2 synthesis and preventing further thrombosis.
• Aortic Syndrome Management: Any patient with Marfan syndrome or connective tissue disorder requiring aortic root monitoring needs aggressive blood pressure control (e.g., beta-blockers) to reduce wall stress and prevent dissection/rupture.
• Coagulopathy in PV: Due to chronic thrombotic episodes, patients may develop acquired von Willebrand Factor deficiency; this requires careful management of bleeding risk alongside thrombosis prevention.

Don't miss

Integration & clinical reasoning

• Connective Tissue Disorders (Marfan): Marfan syndrome is a systemic disorder affecting multiple organ systems (aorta, heart valves, skeleton). Recognizing the aortic risk requires thinking beyond just "dissection" and considering prophylactic screening for dilation/rupture.
• Hematology & Cardiology: Polycythemia Vera links hematology to cardiology by causing hyperviscosity -> increased afterload -> LV hypertrophy -> H FpEF.
• Pharmacology & Genetics (Lithium): The mechanism of cardiac damage from lithium is related to its effect on cellular processes, leading to valve leaflet displacement and structural defects.

OMM / COMLEX integration

• Standard emergency management takes priority in cases of acute aortic dissection (Marfan) or severe bleeding/thrombosis (PV). OMT principles are adjunctive only after stabilization.
• When managing PV-related thrombosis, the focus is on reducing viscosity and preventing further clotting; this requires phlebotomy and antiplatelet agents before considering advanced anticoagulation.

Concept connections / cross-references

• For detailed information on the pathophysiology of connective tissue disorders and aortic risk, see [Episode 123].
• For a comprehensive review of hematologic malignancies and myeloproliferative neoplasms, see [Episode 456].

High-yield association table

Key terms glossary

Study optimization

Question pattern recognition

• Pattern: Polycythemia + Thrombosis + Gout: Strongly suggests Polycythemia Vera (PV), requiring phlebotomy and aspirin.
• Pattern: Tall, thin male + Aortic dilation/dissection: Think Marfan Syndrome; aggressive BP control is paramount.
• Pattern: Bipolar disorder on Lithium -> Cardiac defects: Immediately suspect Epstein's anomaly and associated ASD/PFO.

Test yourself

Common mistakes to avoid

Common traps